LivaNova (NASDAQ:LIVN) Price Target Raised to $80.00

LivaNova (NASDAQ:LIVN) had its price objective upped by Mizuho from $75.00 to $80.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also commented on the company. StockNews.com raised LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Robert W. Baird lifted their price objective on LivaNova from $56.00 to $62.00 and gave the stock a neutral rating in a report on Thursday, February 22nd. Barclays lifted their price objective on LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a report on Monday, February 26th. Finally, Needham & Company LLC restated a buy rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of Moderate Buy and an average price target of $66.20.

LivaNova Stock Performance

NASDAQ LIVN opened at $64.15 on Thursday. The firm has a market capitalization of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.51. The business’s 50-day simple moving average is $54.71 and its 200-day simple moving average is $51.06.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. The business had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The company’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 EPS. Equities analysts predict that LivaNova will post 3.01 EPS for the current year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently made changes to their positions in LIVN. Handelsbanken Fonder AB increased its holdings in shares of LivaNova by 100.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,474 shares of the company’s stock valued at $924,000 after acquiring an additional 8,737 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of LivaNova by 20.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,176 shares of the company’s stock valued at $591,000 after acquiring an additional 1,923 shares during the last quarter. Strs Ohio increased its holdings in shares of LivaNova by 560.0% in the 3rd quarter. Strs Ohio now owns 9,900 shares of the company’s stock valued at $523,000 after acquiring an additional 8,400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of LivaNova by 2.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,202 shares of the company’s stock valued at $1,438,000 after acquiring an additional 544 shares during the last quarter. Finally, Emerald Advisers LLC grew its stake in LivaNova by 5.2% during the 3rd quarter. Emerald Advisers LLC now owns 622,491 shares of the company’s stock worth $32,917,000 after buying an additional 30,636 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.